Back to Search
Start Over
Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience
- Source :
- Journal of Clinical Oncology. 33:531-531
- Publication Year :
- 2015
- Publisher :
- American Society of Clinical Oncology (ASCO), 2015.
-
Abstract
- 531 Background: Pertuzumab is FDA approved for use in combination with trastuzumab and chemotherapy as neoadjuvant therapy in women with non-metastatic HER2+ breast cancer. The TRYPHAENA trial repo...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
medicine.disease
Carboplatin
chemistry.chemical_compound
Breast cancer
chemistry
Docetaxel
Trastuzumab
Internal medicine
Medicine
Non metastatic
Pertuzumab
skin and connective tissue diseases
business
neoplasms
Neoadjuvant therapy
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........75e2875e9fd66f118a6fb450f65c3828
- Full Text :
- https://doi.org/10.1200/jco.2015.33.15_suppl.531